Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. 1988

C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
Johns Hopkins Oncology Center, Pediatric Oncology, Baltimore, MD 21205.

Cell surface phenotypes of 113 B lineage acute lymphocytic leukemia (ALL) cases, defined by the presence of HLA-DR and at least one B-cell-specific antigen (either CD19, CD20, or CD22), were compared with antigen-defined stages of normal B lymphocyte development. The cases were first evaluated for expression of HLA-DR, CD19, CD34, CD10, CD20, and CD22 by indirect one-color immunofluorescence. Pairwise comparisons of cell surface marker expression were performed for each leukemic sample: no correlations were observed for paired antigen expression on the leukemic samples using antigens expressed either early or late during normal B lymphoid development. Complete immunophenotypes of the cases were then compared with normal B-cell developmental stages. Sixteen different complete immunophenotypes were observed on the leukemias that were not found in normal marrow; at least 78% of the cases demonstrated such "asynchronous" combinations of B lymphoid-associated differentiation antigens. Several samples were subsequently studied by two-color immunofluorescence, and the presence of doubly labeled cells with "asynchronous" antigen combinations was confirmed. These results indicate that the majority of B lineage leukemias exhibit "developmental asynchrony," as compared with normal marrow B cells. The data further suggest that ALL cases do not accurately represent cells arrested at the stage where the leukemogenic event occurred. Rather, ALL appears to be a disease in which there may be maturation of leukemic blasts; but this maturation is "asynchronous" when compared with the normal developmental process.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000944 Antigens, Differentiation, B-Lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin. Antigens, Differentiation, B-Cell,B-Cell Differentiation Antigens,B-Lymphocyte Differentiation Antigens,Blast-2 Antigen, B-Cell,Differentiation Antigens, B-Cell,Differentiation Antigens, B-Lymphocyte,Leu Antigens, B-Lymphocyte,Plasma Cell Antigens PC-1,Antigens, Differentiation, B Lymphocyte,Antigens, Plasma Cell, PC-1,B-Cell Blast-2 Antigen,Antigen, B-Cell Blast-2,Antigens, B-Cell Differentiation,Antigens, B-Lymphocyte Differentiation,Antigens, B-Lymphocyte Leu,B Cell Blast 2 Antigen,B Cell Differentiation Antigens,B Lymphocyte Differentiation Antigens,B-Lymphocyte Leu Antigens,Blast 2 Antigen, B Cell,Differentiation Antigens, B Cell,Differentiation Antigens, B Lymphocyte,Leu Antigens, B Lymphocyte,Plasma Cell Antigens PC 1
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent

Related Publications

C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
August 1990, Hematology/oncology clinics of North America,
C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
January 1998, Ryoikibetsu shokogun shirizu,
C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
May 2009, Zhonghua er ke za zhi = Chinese journal of pediatrics,
C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
January 2013, Neoplasma,
C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
September 2016, The New England journal of medicine,
C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
January 1998, Bone marrow transplantation,
C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
May 2012, Leukemia & lymphoma,
C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
September 1981, Blood,
C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
September 1992, Blood,
C A Hurwitz, and M R Loken, and M L Graham, and J E Karp, and M J Borowitz, and D J Pullen, and C I Civin
March 1995, Cancer genetics and cytogenetics,
Copied contents to your clipboard!